

Rule 1.126

<sup>35</sup>  
<sup>32</sup>  
33. The humanized monoclonal antibody of claim 30 wherein the human constant region is IgG.

<sup>36</sup>  
<sup>32</sup>  
34. The humanized monoclonal antibody of claim 30 wherein the human constant region is IgG1-kappa.

<sup>37</sup>  
<sup>32</sup>  
35. The humanized monoclonal antibody of claim 30 wherein the variable region comprises the amino acid sequence of SEQ ID NO: 44.

<sup>38</sup>  
<sup>32</sup>  
36. The humanized monoclonal antibody of claim 30 wherein the variable region comprises the amino acid sequence of SEQ ID NO: 42.

<sup>39</sup>  
<sup>32</sup>  
37. A pharmaceutical composition comprising an antibody of claim 30 and a pharmaceutically acceptable carrier or diluent.

<sup>40</sup>  
<sup>31</sup>  
38. A pharmaceutical composition comprising an antibody fragment of claim 31 and a pharmaceutically acceptable carrier or diluent.

<sup>41</sup>  
<sup>30</sup>  
39. A monoclonal antibody selected from the group consisting of murine 13C4 (ATCC Accession No. CRL 1794), murine 11E10 (ATCC Accession No. CRL 1987), humanized 13C4 (H13C4) and humanized 11E10.

Rule 1.126

#### REMARKS

Claims 303-39 have been added. No new matter has been added by virtue of those claims. For instance, support for those claims appears e.g. in the figures and original claims of the application.

Applicants address as follows comments set forth in the Advisory Action.